WO2011091401A9 - Traitement des maladies du système immunitaire utilisant des antagonistes des récepteurs kaïnate - Google Patents

Traitement des maladies du système immunitaire utilisant des antagonistes des récepteurs kaïnate Download PDF

Info

Publication number
WO2011091401A9
WO2011091401A9 PCT/US2011/022353 US2011022353W WO2011091401A9 WO 2011091401 A9 WO2011091401 A9 WO 2011091401A9 US 2011022353 W US2011022353 W US 2011022353W WO 2011091401 A9 WO2011091401 A9 WO 2011091401A9
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
receptor antagonists
immune disorders
kainate receptor
kainate
Prior art date
Application number
PCT/US2011/022353
Other languages
English (en)
Other versions
WO2011091401A2 (fr
Inventor
Jamie Lynn Sturgill
Daniel Harper Conrad
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Priority to US13/574,808 priority Critical patent/US8952048B2/en
Publication of WO2011091401A2 publication Critical patent/WO2011091401A2/fr
Publication of WO2011091401A9 publication Critical patent/WO2011091401A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
PCT/US2011/022353 2010-01-25 2011-01-25 Traitement des maladies du système immunitaire utilisant des antagonistes des récepteurs kaïnate WO2011091401A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/574,808 US8952048B2 (en) 2010-01-25 2011-01-25 Treatment of immune disorders using kainate receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29787410P 2010-01-25 2010-01-25
US61/297,874 2010-01-25

Publications (2)

Publication Number Publication Date
WO2011091401A2 WO2011091401A2 (fr) 2011-07-28
WO2011091401A9 true WO2011091401A9 (fr) 2011-12-15

Family

ID=44307659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/022353 WO2011091401A2 (fr) 2010-01-25 2011-01-25 Traitement des maladies du système immunitaire utilisant des antagonistes des récepteurs kaïnate

Country Status (2)

Country Link
US (1) US8952048B2 (fr)
WO (1) WO2011091401A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2648515C1 (ru) * 2016-12-21 2018-03-26 Общество с ограниченной ответственностью "ДРД" Прогнозирование течения и исхода комы и посткоматозных бессознательных состояний (в том числе вегетативных) с помощью гемотестов
WO2023172594A2 (fr) * 2022-03-08 2023-09-14 Nova Southeastern University Méthode de traitement de l'arthrite rhumatoïde (ra) à l'aide d'un inhibiteur d'exosite sélectifs d'enzyme et de substrat d'une désintégrine a et d'une métalloprotéase 10 (adam10)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198461A (en) * 1989-12-11 1993-03-30 Neurosearch A/S Isatine derivatives, their preparation and use
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US6156794A (en) * 1996-11-06 2000-12-05 Faiman; Morris Method for treatment of glutamate related disorders

Also Published As

Publication number Publication date
WO2011091401A2 (fr) 2011-07-28
US20130046005A1 (en) 2013-02-21
US8952048B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
HK1188211A1 (zh) 受體拮抗劑
RS55071B1 (sr) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
PL2593095T3 (pl) (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
EP2461809A4 (fr) Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2
SG11201401202YA (en) Antagonists of il17c for the treatment of inflammatory disorders
EP2854816A4 (fr) Formulations pharmaceutiques solides d'un antagoniste de récepteur d'orexine
ZA201306744B (en) Antagonists of the interleukin-1 receptor
EP2967064A4 (fr) Application d'antagonistes du récepteur 5-ht6 afin de soulager les déficits cognitifs du syndrome de down
IL222841B (en) Cadherin-11 antagonist for the treatment of leprosy
IL225896A0 (en) Treatment of mecp-2 related disorders
HK1178902A1 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin b1 receptor b1
HUE045270T2 (hu) FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
ZA201207397B (en) Process for the preparation of dexlansoprazole
EP2566494A4 (fr) Composés de récepteur cxcr4
WO2011091401A9 (fr) Traitement des maladies du système immunitaire utilisant des antagonistes des récepteurs kaïnate
EP2632253A4 (fr) Procédé de préparation d'un antagoniste du récepteur de l'orexine
EP2578206A4 (fr) Composition pharmaceutique pour traiter les affections de la partie inférieure du système urogénital
HK1198580A1 (en) Novel therapeutic use of p75 receptor antagonists p75
GB201007205D0 (en) Treatment of joint disorders
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11735338

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13574808

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11735338

Country of ref document: EP

Kind code of ref document: A2